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HypoxiaLocal administration of therapeutics by inhalation for treatment of lung diseases has the ability to deliver drugs,
nucleic acids and peptides speciﬁcally to the site of their action and therefore enhance the efﬁcacy of the treat-
ment, limit the penetration of nebulized therapeutic agent(s) into the bloodstream and consequently decrease
adverse systemic side effects of the treatment. Nanotechnology allows for a further enhancement of the treat-
ment efﬁciency. The present review analyzes modern therapeutic approaches of inhaled nanoscale-based
pharmaceutics for the detection and treatment of various lung diseases.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Lungs represent an attractive alternative route of drug delivery. They
possess a large area for thedeposition of therapeutics andhigh vascular-
ization for the systemic delivery of various pharmaceutical agents. Inha-
lation lung delivery prevents the degradation of active components in
the gastrointestinal tract and ﬁrst pass metabolism in the liver. Despite
these attractive advantages, systemic inhalation delivery of therapeutics
is still not used widely. Possible high lung toxicity of drugs and their
degradation by lung macrophages, the risk of drug-induced lung injury
and occupational exposure of health care workers to nebulized drugs
limit enthusiasm for the inhalation route for the systemic drug delivery.
On the other hand, the use of systemic delivery of pharmaceuticals for
treating lung diseases in most cases demonstrates a low efﬁciency and
potentially severe adverse side effects on other organs. To enhance the
efﬁcacy of the treatment of various lung diseases and limit exposure of
healthy organs to potentially toxic drugs, it seems natural to deliver
therapeutics directly to the lungs by inhalation. An ideal drug formula-
tion and inhalation delivery method should provide a local inhalation
delivery speciﬁcally to the diseased cells, limit the exposure of healthy
lung cells and restrict drugpenetration into the circulation.While sever-
al efﬁcient inhalation drug delivery devices were already developed,
tested and implemented in clinical practice, the formulation of efﬁcienteutics, Ernest Mario School of
ey, 160 Frelinghuysen Road,
. This is an open access article underdrug delivery systems for local targeted inhalation delivery of various
therapeutic modalities is still in the developmental stage.
Recent advances in nanotechnology open a door for enhancing the
efﬁcacy of inhalation treatment of different lung diseases. The applica-
tion of nanotechnology to the design of drug delivery systems for effec-
tive delivery of therapeutics speciﬁcally to tissues and cells affected by
the disease allows for enhanced treatment outcomes and prevention
of severe adverse side effects upon tissues and cells, including those in
the lungs, as well as entire organs.
The present review analyzes modern nanotechnology approaches
for the local inhalation delivery of various drugs. It describes advantages
and potential limitations of local inhalation drug delivery and discusses
different types of drug delivery systems suitable for inhalation with a
special emphasis on nanoparticle-based delivery vehicles. The review
also analyzes modern therapeutic applications of inhalation delivery
with an accent on the treatment of lung cancer andmetastases. In addi-
tion this review brieﬂy describes modern patents related to the inhala-
tion drug delivery and recent clinical trials of therapeutics for treatment
of lung diseases. Finally, it also describes future directions in nanotech-
nology approaches for inhalation treatment of lung diseases.
2. Inhalation local delivery
The term inhalation local delivery is used inmost cases to denote in-
halation route of delivering therapeutics or other exogenous entities di-
rectly to the lungs with their preferential accumulation in the speciﬁc
lung areas or cells and limited penetration into the blood circulation.
This type of inhalation delivery is especially useful for treating various
lung diseases. It is expected that such delivery method will transportthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the required time. The efﬁciency of inhalation local delivery mainly de-
pends on lung aerodynamics, breathing conditions, particle size, inhala-
tionmethods and devices used [1–8]. To be inhaled, a delivered liquid or
solid should be suspended in a gaseousmedium to form an aerosol [4,5,
9–17]. In the present review, wewill not discuss these factors as well as
delivery devices andwill instead focus our attention on the engineering
of nanotechnology-based delivery systems that are being used for the
local inhalation delivery of therapeutics to the lungs. For the detailed
discussion of the inﬂuence of different types of aerosols, particle size,
lung aerodynamics and inhalation devices on the efﬁcacy of inhalation
lung delivery, the reader is referred to the above cited manuscripts.
2.1. Advantages of inhalation local delivery
Major advantages of inhalation route of drug delivery locally to the
lungs in order to treat lung diseases include direct delivery of active
components to the diseased organs and cells, prevention of potentially
toxic therapeutics from entering the bloodstreamand therefore limiting
possible adverse effects upon other healthy organs (Fig. 1). Moreover,
if the inhaled delivery system is speciﬁcally targeted to diseased cells
(e.g. cancer cells), then healthy lung cells will also be protected from
the drug or other inhaled exogenous substances. An efﬁcient delivery
system speciﬁcally designed for the local inhalation lung delivery
should therefore retain in the lungs or even preferably, speciﬁcally in
the diseased cells for the required treatment period and not penetrate
in its active form into the bloodstream in order to protect the rest of
the body from the potentially toxic exposure.
2.1.1. Organ distribution
Local inhalation delivery of therapeutics in most cases substantially
changes the organ distribution of delivery system and its active compo-
nents in the organisms when compared with oral or parenteral delivery
[17–24]. Although various carriers have different body distributions, a
general tendency in the body distribution of nanocarriers with size lessFig. 1. Advantages and challengesthan 1 μmconsists of the following [19]. After intravenous (systemic) de-
livery, the majority of the injected particles is accumulated in the liver,
kidney and spleen (Fig. 2) [18]. A certain amount of nanoparticles
(often about one quarter of an injected dose) accumulates in the lungs.
Therefore, about 75% of the injected dose will most likely be lost for
the treatment of lung diseases. Thiswill not only reduce treatment efﬁca-
cy, but will require higher doses to compensate an unfavorable drug dis-
tribution and potentially can induce severe adverse side effects on other
organs. In contrast, some types of nanoparticles (liposomes, nanostruc-
tured lipid carriers, mesoporous silica nanoparticles, anisotropic
polymer/lipid “Janus” particles, etc.) preferentially accumulate in the
lungs after inhalation (Fig. 2) [18,19,21–25]. Consequently, even if
nanocarriers are not targeted speciﬁcally to the lung cancer cells, so-
called passive targeting [26] (in our case by a local inhalation delivery di-
rectly to the lungs)will enhance organ distribution. It should however be
stressed, that targeting a drug speciﬁcally to lung cells (or cancer cells in
the case of lung cancer) will change the distribution of intravenously
injected nanoparticles toward their preferential accumulation in the
lungs. However, local inhalation delivery of targeted nanoparticles will
further improve the distribution proﬁle, and therefore still will have ad-
vantages over the systemic delivery.2.1.2. Pharmacokinetics
Local inhalation delivery of pharmaceutics directly into the lungs in
most cases improves pharmacokinetics of the delivered agent(s). Gen-
erally, it increases the retention of the delivered drug in the lungs [17,
19]. The area under the curve for overall drug retention in the lungs,
half-life and maximal concentration of the drug in the lungs and lung
tissue was increased greater for a local inhalation lung delivery when
compared with systemic exposure (Fig. 3) [14]. Taken together, the im-
provements in the drug organ distribution and pharmacokinetics allow
for decreasing the overall drug concentration needed for achieving the
maximal therapeutic efﬁciency and substantially limiting adverse side
effects upon healthy organs and tissues.of pulmonary drug delivery.
Fig. 2.Advantages of inhalation drug delivery: improved organ distribution. Organ distribution of liposomes (A) and nanostructured lipid carriers (NLC, B) after intravenous and inhalation
delivery.
Modiﬁed from Ref. [18].
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Despite marked advantages of inhalation delivery for the treatment
of lung diseases, some factors can potentially limit the practical imple-
mentation of this approach in the clinic. These limitations include sever-
al technological challenges associated with inhalation [27] and more
general concerns related to the approach itself [4]. The later challenges
are brieﬂy discussed below.
2.2.1. Lung toxicity of drugs
When a drug or other biologically active substance is delivered via in-
halation, the lungs are inherently exposed to its action and open a possi-
bility of side effects. This is especially important in case of highly toxic
anticancer drugs. Consequently, a major obstacle for systemic inhalation
chemotherapy includes a fear that inhalation of highly toxic anticancer
drug(s) may induce severe undesirable secondary effects on the lungs.
Such a problem is less important when the cancer resides inside the
lungs and therefore chemotherapeutic toxic effect is applied directly to
the site of its action. In this case, the delivery of toxic chemotherapeutic
substances directly into the lungs with limited penetration into the
bloodstream may even protect the rest of the body from undesirable
toxic effects of the treatment. However, when the toxic substance used
for treatment distributed equally via the lung parenchyma, both diseased
(e.g. cancer) and healthy lung cells potentially are exposed to the drug. In
order to avoid this undesirable exposure of healthy cells, chemothera-
peutic agent(s) or other drug(s) can be speciﬁcally targeted to the dis-
eased cells.
2.2.2. Drug induced lung disease
Contemporary drugs usually are very potent. This not only enhances
the efﬁcacy of treatment of different diseases, but also increases the riskFig. 3. Advantages of inhalation drug delivery: improved pharmacokinetics. The area under the
drug (5-azacytidine) in the blood and lungs after systemic and aerosol delivery.
Plotted based on data from Ref. [14].of undesirable side effects on healthy tissues. Being delivered by inhala-
tion, some drugs can potentially induce lung damage, provoke the de-
velopment of lung disease or increase the severity of existing ones. It
was found that about 400 drugs can potentially induce different lung
diseases [28]. Again, this problem is especially important in the case of
lung cancer and associated inhalation chemotherapy. In many cases
lung cancer or/and lungmetastases are accompanied by other lung dis-
turbances. Consequently, many patients with lung cancer have im-
paired pulmonary functions due to smoking and/or chemotherapy.
Inhalation of toxic chemotherapeutic agents potentially can affect and
further increase these complications. As was mentioned above,
targeting of inhaled drug(s) speciﬁcally to diseased cells can help allevi-
ate the problem.
2.2.3. Occupational exposure
Healthcare workers involved in providing inhalation therapy can be
potentially exposed to the nebulized drug(s). In addition to systemic
treatment,where personnel can also be exposedduring thepreparation,
injection and disposal of the toxic agent, exhalation of residual amounts
of aerosol represents a serious threat to thehealth of healthcareworkers
that routinely perform the treatment procedures. Fortunately, recently
developed ﬁlters and air cleaning systems substantially minimized
such risk [4]. Nevertheless, the possibility of exposure of healthworkers
to the dangerous aerosols should be considered as a hazard during inha-
lation therapy and minimized by corresponding measures.
2.2.4. Lung defense mechanisms
The lung represents an organ in the human body that is systemati-
cally exposed to different and often damaging parenchyma substances.
Naturally during evolution, many defensive mechanisms were devel-
oped in the lungs in order to limit exposure to potentially dangerous
substances and minimize the damage caused to the lung structurescurve (AUC, A), half-life (B) and maximal concentration (Cmax, C) of delivered anticancer
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mucus, macrophages, transporters and enzymes [11,29]. In addition,
manifestations of lung disease(s) and impaired pulmonary function
canpotentially interferewith inhalation therapy andprevent deposition
of aerosols into the desired regions of the lungs or cellular uptake of the
therapeutics. Consequently, inhalation devices, regimens and delivery
systems should be designed regarding these obstacles. It should be
stressed however, that lung defensive mechanisms much less affect
the local inhalation treatment of lung diseases when compared with
systemic inhalation delivery. Nevertheless, lung defense mechanisms
must be taken into accountwhen designing delivery systems for inhala-
tion therapy. In addition to drug(s), such complex systems may include
additional components that help to overcome or suppress lung defen-
sive mechanisms. For example, in order to defeat cellular drug efﬂux
transporters that pumps out drugs from the lung cells, suppressors of
corresponding proteins (e.g. nucleic acids or small molecules) can be in-
cluded into a complex delivery system [20,24]. Similarly, suppressors of
cellular anti-apoptotic resistance can also be included in the system in
order to enhance cell death induction by anticancer drug(s) [22,23]. It
should also be taken into account, that the complexity of the delivery
system substantially increases its cost and makes the production sub-
stantially more complicated.
2.2.5. Drug stability
A therapeutic agent should not drop its activity during the process of
nebulization and its travel to the site of action [30]. The later seems to be
less important when drug is delivered directly to the lungs for treating
of lung diseases. Drug destruction during the nebulization depends on
the type of nebulizer and regimen of inhalation. Special constructions
of nebulizers were developed in order to protect the integrity of drug
delivery systemand prevent drug degradation during aerosol formation
[17,30]. A detail discussion of such devices is out of the limits of the
present review.
2.3. Drug targeting
Generally, two types of targeting approaches are distinguished: pas-
sive and active targeting [26]. In case of cancer, the so-called Enhanced
Permeability and Retention (EPR) effect is often used for tumor
targeting when a drug is delivered using systemic administration
[31–33]. Enhanced permeability of tumor blood vessels and poor lym-
phatic drainage leads to the preferential accumulation of high molecu-
lar weight substances in solid tumors. It is understandable, that the
EPR effect cannot play a substantial role in passive tumor targeting
when an anticancer drug is delivered by a highmolecularweight carrier
via inhalation. However, the fact of delivering drug(s) directly into the
lungs provides a passive targeting to this organ. In addition, the selec-
tion of a right size of delivered aerosol particles helps to target a speciﬁc
region of the lungs. It is generally believed that aerosol particles with
meandiameter of 5–10 μmare preferentially deposited into oropharynx
and large conducting airways [4]. In contrast, smaller particles with di-
ameter less than 1–5 μm are deposited in the small airways and alveoli.
Consequently, based on the primary location of the diseased cells inside
the lungs, the optimal selection of particle sizemay potentially help tar-
get certain regions of the lungs. However, it is unlikely that particles
with size of 1 μm and higher can be effectively taken by lung cells. It
was found that particles with the size of 100–150 nm internalized 8–9
times better by cancer cells when compared with similar particles
with the size of 3–5 μm [34]. Consequently, when large particles are
used as drug carriers, the drug must be released after their accumula-
tion in a close proximity to the targeted cells.
The application of so-called “active targeting” [26] methods may
help in targeting delivery system and/or drug(s) speciﬁcally to the dis-
eased or cancer cells. In particular targeting cell surface receptors, intra-
cellular organelles and molecules may be useful for active targeting in
case of inhalation delivery of pharmaceutics. Many different activetargeting approaches were developed during the last two decades and
tested in experiments and in clinics [26,35–41]. One of such active
targeting approaches was developed and evaluated in or laboratory
and is based on targeting luteinizing hormone releasing hormone
(LHRH) receptors [22,38,42–46]. We found that LHRH receptors
overexpressed in the plasmamembrane of various cancer cells (includ-
ing lung cancer cells)while their expression in healthy cells from viscer-
al organs normally does not exceed the detection level of modern
polymerase chain reactionmethod. Consequently, when the LHRH pep-
tide in its native or modiﬁed form is added to the delivery system, the
entire system and delivered drug is accumulated predominantly in can-
cer cells leaving healthy ones intact. Such targeting approach was suc-
cessfully applied for the inhalation delivery of nanoparticle-based
drugs and nucleic acids speciﬁcally to lung cancer cells (Fig. 4) [23]. It
was found that non-targeted nanostructured lipid carriers (NLC) were
relatively uniformly distributed within the lungs including healthy
lung tissues. In contrast, LHRH-targeted NLC predominately accumulat-
ed in lung tumor nodules with minimal accumulation of the particles
and drugs in healthy tissues.
3. Delivery systems
Many different types of dosage forms have been developed for dif-
ferent routes of drug delivery. Not all systems are suitable for inhalation
delivery. However, several types of drug delivery systems were devel-
oped and tested for the administration of different drugs by inhalation.
The majority of these types of delivery systems include colloidal disper-
sions, differentmicroparticles and nanoparticles. These inhalation deliv-
ery systems are brieﬂy described below.
3.1. Colloidal dispersions
Colloidal system or colloidal dispersion for drug delivery represents
a heterogeneous system which consists of a dispersed phase (solid or
liquid drug) homogenously distributed within the dispersion medium
(usually water). The simplest way to produce aerosols of water insolu-
ble drugs is a dispersion of the solid or liquid hydrophobic drug in
water using probe sonication. The resulting colloidal dispersion can be
used to produce aerosols by different methods and then delivered into
the lungs by inhalation. An example of such system is tacrolimus disper-
sion designed for nebulization and inhalation delivery to the lung
transplanted rodent model [47,48]. An average aerodynamic diameter
of the resulted nebulized drug dispersion was 4 μm. The developed sys-
tem was successfully used to deliver tacrolimus locally to the lungs and
was successfully tested using a lung transplanted rodentmodel. The ex-
perimental results demonstrated effectiveness of such a colloidal sys-
tem in the prevention of lung allograft rejection in lung transplant
recipients and limitation of systemic adverse side effects.
3.2. Microparticles
The term “microparticle” in drug delivery applications generally refers
to a particle with one or several micrometers in size. According to the In-
ternational Union of Pure and Applied Chemistry (IUPAC), a nanoparticle
represents a particle with dimensions between 1 × 10−7 and 1 × 10−4 m
[50]. However, it is stressed that the lower limit of the distinguishing be-
tweenmicro- and nanoparticles is still debatable. In our opinion, in terms
of usefulness for the delivery of drugs, the particles with dimensions
lower than 0.5 μmshould be referred to as nanoparticles (Fig. 4) [49]. Mi-
croparticles of many materials including ceramics, glass, polymers, and
metals are currently commercially available. However, polymer and
metal microparticles are being mainly used for the drug delivery pur-
poses. Paclitaxel loaded alginate microparticles represent a typical exam-
ple of microparticles designed for inhalation delivery and built using a
natural polymer–alginic acid [51]. Alginate represents a biocompatible,
biodegradable and mucoadhesive polymer that effectively binds to
Fig. 4. Distribution of ﬂuorescently labeled (Cy5.5) non-targeted and LHRH-tumor targeted nanostructured lipid carriers (NLC) inmouse lungs bearing human lung cancer. NLC were de-
livered by inhalation. (A) Representativeﬂuorescence imaging using IVIS system of excised entire lungs. (B) Representative bright ﬁeld and ﬂuorescencemicroscope images of frozen lung
slices. Red color represents distribution of NLC-LHRH in tumor and non-tumor lung tissues.
Modiﬁed from Ref. [23].
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emulsiﬁcation technique, loaded with paclitaxel and characterized.
Their size ranged from 3 to 10 μm. Microparticles with a mean volume
diameter of 3 ± 0.7 μm, mass median aerodynamic diameter of 5.9 ±
0.33 μm, and drug encapsulation efﬁciency of 61 ± 4% were found to be
the best suitable for pulmonary delivery.
3.3. Nanoparticles
In general, nanoparticle represents particleswith sizes at least in one
direction smaller than 500 μm(Fig. 5) [49,50]. They normally form a sta-
ble colloidal dispersion. Currently, nanoparticles are widely used for
drug transport via various delivery routes, including inhalation. DuringFig. 5. Classes of nanoscale drug delivery systems (bottom panel) and examples of polymeric
Modiﬁed from Ref. [49].inhalation delivery, nanoparticles can form droplets or aggregates
with higher micrometer size. However, a major behavior of these parti-
cles after the deposition inside the lungs depends on their nanoscale
range dimensions.
The composition, size and shape of nanoparticles signiﬁcantly inﬂu-
ences their retention in the lungs and targeting properties [19]. However,
recentlywe showed that speciﬁc active targeting of various nanoparticles
to cancer cells (andpossibly to other diseased cells) diminishes the differ-
ences between various nanocarriers as drug delivery vehicles [38].
3.3.1. Polymers
Polymers of different composition represent a major part of
nanotherapeutics that are used for drug delivery via various routes,drug delivery systems polymer molecules are represented by dark red color curved lines.
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cles included polymers (Fig. 6). Consequently, it is hard to distinguish
between different forms of polymer-based delivery systems. Tradition-
ally, we consider as a “polymeric” drug delivery system compositions
that have a linear polymer conjugated with active components of the
system (drugs, targeting moieties, etc.) directly or via spacers of differ-
ent architecture (Fig. 6A).
Many different types of polymers are used for creating delivery
systems. However, only a limited number of them are suitable for
local pulmonary inhalation delivery. The examples of polymeric sys-
tems for inhalation delivery of drugs include poly(lactic-co-glycolic)
and poly(ethylene glycol)-co-poly(sebacic acid) aerosol dry powder
formulations [52,53]. Because of the relatively small size, carriers
comprised from a “pure” linear polymer can easily penetrate into
the systemic circulation and open a door for adverse side effects. In
addition, an administration to the organism of exogenous polymeric
materials can potentially cause adverse effects. Consequently, poly-
mers are mainly used in a complex with other molecules (e.g. nucleic
acids or lipids) to form nanoparticle-like structures (Figs. 5, 6).
3.3.2. Dendrimers
The termdendrimer (fromaGreekwordDendron— tree) usually de-
note a highly branched structure (Fig. 6B). The size of most dendrimers
used as drug carriers varies from 4 to 20 nm. While this size provides
for an efﬁcient internalization by different targeted cells, dendrimers
usually rapidly penetrate into the circulation minimizing their retention
in the lungs. For instance, doxorubicin was conjugated to a 56 kDa
PEGylated poly-lysine dendrimer and studied for anticancer efﬁcacy
[54]. It was found that the dendrimer was rapidly removed from the
lungs (within 24 h) after intratracheal instillation. Finally, only around
15% of the instilled drug was retained in the lungs. However, even with
this relatively unfavorable pharmacokinetics, intratracheally adminis-
tered drug (twice per week) led to almost complete regression of the
lung tumor. In contrast, intravenously delivered doxorubicin solution re-
duced tumor by only 30–50%. However, dendrimers are often used as a
component ofmore complex delivery systems resulting in the formation
of larger nanoparticles that potentially can be employed for the inhala-
tion delivery [45,55–61]. For instance, surface or internally charged
dendrimers were successfully employed in our laboratory for delivery
of nucleic acids [55–57,60,62].
3.3.3. Lipid-based nanoparticles
Lipid-based nanoparticles are used extensively for various drug de-
livery applications. These nanocarriers allow for easy incorporation of li-
pophilic drugs in its lipid core/membrane (Fig. 6C, D). The amphiphilic
nature of many lipids allows them to form various structures and incor-
porate hydrophilic drug molecules as well (Fig. 6C). In addition, lipid
carriers can be made from biocompatible lipids similar to those that
comprise cell membrane. This not only limits toxicity of lipid carriers,
but allows them to easily penetrate inside different cells. Moreover, li-
pophilic nature of the carriers permits the crossing of the blood–brain-Fig. 6. Examples of different architecture of delivery systems (polym
Modiﬁed from Refs. [18,49].barrier under certain conditions allowing brain drug delivery. In terms
of inhalation lung delivery, lipid particles can be easily aerosolized and
usually are well taken by the lungs providing for a prolonged retention
of carriers and drugs in the lungs [19].
3.3.3.1. Lipid nanoparticles. It seems natural to choose lipids similar
to those contained in lung surfactants in order to form carriers for
inhalation lung delivery. Dipalmitoylphosphatidylcholine (DPPC) and
dipalmitoylphosphatidylethanolamine-methoxy(polyethyleneglycol)
(DPPE-PEG) are often used for these purposes. For instance, a micro/
nanoparticle DPPC/DPPE-PEG system was used for dry powder inhala-
tion delivery of the anticancer drug paclitaxel [63,64]. Different spray-
dried micro/nanoparticles with a size of 0.6–3.4 μm were prepared
and characterized. These delivery systems demonstrated a satisfactory
drug loading capacity and potential for inhalation chemotherapy.
3.3.3.2. Liposomes. Liposomes probably are themostwidely used and best
characterized lipid-based drug carriers. In most cases, a typical liposome
consists of a single bilayer lipid membrane (unilamellar liposomes)
(Fig. 6C) or several bilayer lipid membranes (multilamellar liposomes).
The outer surface of liposomes is often modiﬁed by polymers (mainly
poly(ethylene glycol), PEG). Such coating performs several functions. It
adds STEALTH properties to the liposomes and allows for conjugating ad-
ditional components of the delivery system (e.g. targeting moiety) to the
distal end of the polymer [65–68]. In most cases liposomes suitable for
drug delivery have a size range of 50–500 nm,while larger size liposomes
are also been employed (Fig. 5) [49]. It also should be stressed, that by
varying a composition of liposome membrane(s), a neutral, negatively
charged and cationic liposomes may be created. The later liposomes can
be used to form complexes with negatively charged nucleic acids [69].
Liposomes were extensively tested as vehicles for the inhalation de-
livery of drugs, vitamins and nucleic acids for treatment of several dis-
ease and pathological conditions [4,5,19–21,67,68,70–75]. Many
known and new techniques have been tested for nebulization of lipo-
somes and delivering them as a dry powder [4,5,17,71]. In most cases,
after carefully selecting liposome composition andmethods of liposome
nebulization, liposomes preserve their size, payload and do not aggre-
gate after aerosolization. They demonstrate a preferential accumulation
in the lungs (Fig. 2A), suitable lung retention for an extended period,
penetration into lung cells after inhalation (Fig. 7A), and release of ac-
tive payload inside the cells (Fig. 7B) [21,74]. In most cases, no signiﬁ-
cant adverse side effects were registered after the application of
neutral or slightly negatively charged liposomes. However, cationic li-
posomes were found to be toxic to human cells and potentially can in-
troduce genetic aberrations [58]. Moreover, adverse side effects of
cationic liposomes signiﬁcantly increased with an increase of positive
charge of the particles. However, because cationic liposomes normally
are used for the formation of almost neutral complexes with negatively
charged nucleic acids, such modiﬁcation of cationic carriers usually
prevents adverse effects on the cells [58].er molecules are represented by dark red color curved lines).
Fig. 7. Localization of liposomes (A) after the inhalation delivery and the release of doxorubicin (B) in themouse lung cells. Liposomeswere labeled by osmium tetroxide and visualized by
electron transmission microscopy. Doxorubicin was visualized using ﬂuorescence microscopy.
Modiﬁed from Refs. [21,74].
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different types of lipid nanoparticles, polymers can be used to form
lipid–polymer hybrid nanoparticles as an alternative to other lipid-
based nanocarriers including liposomes [15,16]. Poly(lactic-co-glycolic
acid) nanoparticles enveloped by phosphatidylcholine (PC) or PC-
stearylamine layers were tested as lipid–polymer hybrid nanoparticles
for inhalation delivery. The resulting nanoparticles were spherical in
the shape and were adsorbed onto the carrier chitosan particles. It
was suggested, that the resulting particles should have an aero-
dynamic diameter between 1 and 5 μm because nanoparticles smaller
than 1 μm could be exhaled back while particles larger than 5 μm
could be deposited in the mouth and throat regions, instead of the
lungs. However, the suggestion that nanoparticles can be exhaled and
not deposited in the lung tissues and cells contradict an extensive liter-
ature data showing that lipid-based nanoparticles with the size smaller
than 1 μm are successfully deposited and retained in the lung tissues
and also penetrate into the lung cells (Figs. 2, 7 and cited above
references).
Another hybrid polymer/lipid nanoparticles, suitable for inhalation
lung delivery so called “Janus” nanoparticles were developed in our lab-
oratory (Fig. 8) [25]. These nanoparticles have two distinct
phases—polymeric phase, which can be loaded with water-soluble
drug(s) (e.g. doxorubicin), and lipid phase, that can be loadedwith lipo-
philic drug(s) (e.g. curcumin). These nanoparticles preserved their
shape, size distribution and drug loading during nebulization, and
were highly effective in treatment of orthotopic murine model of lung
cancer.Fig. 8. Anisotropic polymer/lipid “Janus” nanoparticles Representative scanning electron micro
ticles. Polymeric phase of nanoparticles was labeled with FITC (green ﬂuorescence); lipid phas
Modiﬁed from Ref. [25].3.3.3.4. Nanostructured lipid carriers. Nanostructured lipid carriers (NLC)
represent a new generation of lipid nanoparticles suitable for inhalation
delivery of different drugs and siRNA (Fig. 6D) [23]. NLC are prepared
frommixtures of solid (e.g. Precirol ATO 5) and spatially incompatible liq-
uid lipids (e.g. Squalene) by melt-emulsiﬁcation. Lipophilic drug can be
loaded into the inner core of NLC. These particles can be made positively
charged by using a cationic lipid(s) (e.g.N-[1-(2,3-dioleoyloxy)propyl]-
N,N,N-trimethylammoniummethyl-sulfate, DOTAP) for their fabrication.
Such cationic nanoparticles can form complexes with negatively charged
nucleic acid molecules. Alternatively, thiol-modiﬁed DNA or RNA mole-
cules (e.g. small interfering RNS, siRNA) can be conjugated to the surface
of NLC via biodegradable disulﬁde (S–S) bonds (Fig. 6D). In addition, the
surface of the NLC can be modiﬁed with PEG polymer conjugated with
targeting moieties (e.g. LHRH peptide for cancer cell targeting). Testing
of NLC containing paclitaxel for cell death induction and siRNAs targeted
to MRP1 and BCL2 mRNAs as suppressors of cancer cell resistance and
anti-apoptotic defense for inhalation chemotherapy of lung cancer
showed their exceptional therapeutic efﬁcacy [23].
3.3.4. Nanospheres
A novel class of synthetic carriers designed mainly for gene delivery
was proposed [76]. These nanospheres were synthesized using
four poly-ethyleneoxide/polypropylenoxide blocks centered on an
ethylenediamine moiety. The nanoparticles had a positive charge and
easily formed complexeswith nucleic acids/plasmids. Later, these nano-
sphereswere successfully used for inhalation delivery of the chemokine
fractalkine as a cancer chemotherapeutic agent [77]. In vivo testingscopy (A) and ﬂuorescence (B) images of polymer/lipid “ice cream cone” shaped nanopar-
e was labeled with DiR (red ﬂuorescence).
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and osteosarcoma supported the use of these nanospheres as promising
immunotherapeutic approach.
3.3.5. Complexes with nucleic acids
Low stability of nucleic acid in the plasma and other body ﬂuids and
tissues as well as its poor penetration inside the cells via the plasma
membrane substantially limits the application of free nucleic acids.
This is especially important for inhalation delivery of nuclei acids
where the destructive inﬂuence of nebulization on the fragile nucleic
acid molecules aggravates its damage and destruction. Two generic ap-
proaches are usually used for delivery of nucleic acids using non-viral
vectors. The ﬁrst approach includes a complex formation between neg-
atively charged nucleic acid molecules and positively charged carrier
materials. As the result of the complex formation, positively charged
nanoparticles are formed. The second approach for the delivery of
nucleic acids comprises a direct conjugation of a modiﬁed nucleic acid
molecule to the carrier via a biodegradable chemical bond.
Polyethylenimine (PEI) and its derivatives as well as DOTAP are most
widely used carriers for gene delivery. However, PEI andDOTAP are cyto-
toxic [12,58]. Consequently, other alternatives (e.g. PAE-poly(amino
ester) based on glycerol propoxylate triacrylate and spermine) gene car-
riers have been proposed as PEI and DOTAP alternatives [12]. In addition,
practically all types of cationic carriers are suitable for complexationwith
nuclei acids and their inhalation delivery [10,12,13,22,23,55–57,78–82].
In particular, glucosylated polyethylenimine, chitosan, spermine-alt-
poly(ethylene glycol) polyspermin, polypropylene Imine (PPI), silica
and other substances have been successfully used to form nanoparticle
carriers for inhalation delivery of nucleic acids.
In most cases, cationic carriers used to form complexes with nucleic
acid molecules have positive charges on their surface. In contrast, we
proposed nanoparticles for DNA complexation with inner positive
charges and modiﬁed surface for the effective protected delivery of
nucleic acids in order to cover them (at least in part) with dendrimers
[55]. In addition, a special caging of nanoparticle-DNA/RNA complexes
has been proposed in order to protect them from harsh actions of the
environment [59]. Mesoporous silica nanoparticles have also been test-
ed for simultaneous inhalation delivery of anticancer drug(s) and siRNA
[22]. The advantages of these nanoparticles include development of in-
ternal sealed pores that can protect a drug from degradation and conju-
gation of modiﬁed nucleic acid on their surface.
3.3.6. Magnetic nanoparticles
Magnetic nanoparticles can be used for imaging and drug delivery.
When such particles accumulate in the targeted site they can be used
as contrast agents for magnetic resonance and other contrast imaging.
These nanoparticles can be targeted to the site of action by an external
magnetic ﬁeld. In addition, the application of high intensity external
magnetic ﬁelds raises the temperature of such nanoparticles comprised
mainly ofmetals. High temperature can be used for killing targeted cells
(e.g. foci of bacterial infection or tumor nodules). The application of
magnetic nanoparticles for inhalation local lung delivery has also been
proposed and evaluated [83–85]. A simple superparamagnetic iron-
oxide nanoparticles (SPIONs), or more complex surface coated of
Fe3O4 magnetic nanoparticles with polymer poly(lactic-co-glycolic
acid) and lipid-coated SPIONs have been used for these purposes.
4. Therapeutic applications of inhalation delivery
As was described above, the delivery of therapeutics to the lungs by
inhalation demonstrates a high potential for treatment of lung diseases.
In this case, local pulmonary delivery of drugs and/or other active com-
ponents directly to the site of disease enhances therapeutic efﬁcacy of
the drugs, allows for a decrease of drug concentration, and limits drug
penetration into the circulation preventing severe adverse side effectsupon healthy organs and tissues. Below we discuss major therapeutic
applications of inhalation delivery.
4.1. Asthma and chronic obstructive pulmonary disease (COPD)
Treatment andmanagement of asthma andCOPD is themost known
application of inhalation delivery of therapeutic agents. Various types of
β agonists, anticholinergics, corticosteroids anti-inﬂammatory drugs
are effectively delivered by inhalation [8,86–91]. In the present review,
wewill focus on the application of inhalation delivery for diseases other
than asthma and COPD.
4.2. Lung hypoxia and edema
Tissue hypoxia accompanies many lung diseases (lung edema, pneu-
monia, ﬁbrosis, etc.), aggravates the primary disorder, and causes addi-
tional cell damage [69,70,92]. Consequently, remediation of cellular
hypoxia may help in treatment of primary disease. Despite relatively
large number of anti-hypoxic preparations, only limited attempts were
made to deliver themby inhalation. In our lab, we developed a liposomal
form of α tocopherol that can be delivered to the lungs by intratracheal
injection or by inhalation [70]. It was found that the major mechanisms
of anti-hypoxic action of liposomal α tocopherol included the following
(Fig. 9) [92]. It should be stressed that liposomes used in this study
were comprised with phosphatidylcholine — a major component of
lung surfactant system. Consequently, delivery of this phospholipid nor-
malized at least in part its deﬁciency caused by severe hypoxia. This in
turn improved lung biomechanics, breathing pattern and increased oxy-
gen consumption. Inhibition of lipid peroxidation by the supplied vita-
min E decreased hypoxic damage of air–blood barrier and also limited
cellular damage caused by oxygen reactive species. Taken together all
these factors limited hypoxic cellular damage, lactate-acidosis, and
prevented cell death from apoptosis and necrosis. Consequently, the re-
sistance of an entire organism against acute severe hypoxia signiﬁcantly
increased. As a result, the mortality of animals with hypoxia was sub-
stantially decreased after the treatment with liposomal α tocopherol.
4.3. Lung injury
Potentially, inhalation delivery of drugs can help to minimize lung
injury caused by the damaging environmental impacts. For instance, it
was shown that inhalation delivery of kinase-deﬁcient Akt1 gene that
encodes one of serine/threonine-protein kinases attenuates injury of se-
cretory Clara cells induced by naphthalene [13]. These types of cells
function in innate defense and epithelial repair. Consequently, limiting
of their damage potentially can be useful forminimization of adverse ef-
fects caused by some type of treatments (e.g. chemotherapy) or damag-
ing impacts of various environmental factors.
4.4. Lung transplantation
The rejection of lung allograft after the transplantation represents a
major problem. Immunosuppressive therapy demonstrated a potential
on increasing the success rate of transplantation of several organs and
bone marrow. In most cases, immunosuppressive agents are delivered
systemically, mostly by parenteral injections. However, in case of lung
transplantation, it is logical to deliver such agents directly to the lungs
in order to suppress lung transplant rejection and limit adverse side ef-
fects on the overall body immunity. Several delivery systems were pro-
posed and tested for inhalation delivery of tacrolimus [47,48,93]. In
these studies, tacrolimus powder reconstituted in deionized water and
amorphous or crystalline nanoparticles of the drug produced by the
ultra-rapid freezing method were used. The results showed a high po-
tential of inhalation form of tacrolimus in limiting the rejection rate of
lung transplants.
Fig. 9. Correction of hypoxic lung damage by liposomal α tocopherol.
Modiﬁed from Ref. [92].
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The risk of lung fungal infections increased in patients undergoing
chemotherapy, organ and cell transplantation or treated in intensive
care units. However, pulmonary infections often poorly respond to the
systemic treatments due to the low accumulation of antifungal drugs in
the lungs [94]. Several attemptsweremade in order to deliver antifungal
drugs via inhalation. A 2-hydroxypropyl-β-cyclodextrin (HPβCD) solubi-
lized itraconazole (ITZ) solution (i.e., HPβCD-ITZ) and colloidal disper-
sion of ITZ were created and delivered as aerosol to mouse lungs [95].
The analysis of pharmacokinetics and distribution pattern showed that
both formulations are suitable for local inhalation delivery to the lungs.
In another independent study, aerosolized commercially available
voriconazole solution was tested for the prevention of invasive pulmo-
nary aspergillosis [96]. The results showed clear advantages of
voriconazole delivered via inhalation over amphotericin B deoxycholate
delivered intraperitoneally (Fig. 10). In fact, mice treated with the in-
haled drug had fewer signs of invasive disease.
4.6. Pulmonary ﬁbrosis and inﬂammation
Idiopathic pulmonary ﬁbrosis (IPF) often accompanied by inﬂam-
mation is a devastative lungdisease that is often associatedwithmortal-
ity. Treatment of this disease is difﬁcult because an effective therapy is
not available yet. We proposed to use liposomal form of prostaglandin
E2 for treatment of IPF via inhalation [21]. The formulation was tested
on experimental mouse model of IPF and inﬂammation caused by
intratracheal administration of bleomycin. It was found that treatment
of animals with such a liposomal formulation decreased the signs of
IPF, blocked overexpression of many proteins involved in the develop-
ment of IPF, inﬂammation and ﬁbrotic lung injury and ﬁnally prevented
animal mortality.
4.7. Lung cancer and metastases
Lung tumor represents a one of the most deadly and poorly treated
cancer diseases. In addition, many other types of cancers often resultin the development of lungmetastases in the advanced stage of the dis-
ease. Most existing systemic therapies (administered by intravenous or
oral routes) are not very effective for the treatment of primary lung can-
cer andmetastases and/or induce severe adverse side effects. Inhalation
(local drug delivery) would be an important part of combination thera-
py togetherwith systemic or local treatment of lung cancer, especially of
itsmetastases to other organs [97]. Consequently, local pulmonary inha-
lation delivery of anticancer agents potentially can improve the out-
come of lung cancer therapy.
4.7.1. Rationale and limitations
The rationales for inhalation cancer treatment are essentially similar
to pulmonary therapeutics for treatment of other pulmonary diseases
[8,98,99]. The delivery of highly toxic anticancer drug(s) locally to the
lungs allows for decreasing the total drug concentration and preventing
its penetration into the bloodstream and therefore limiting adverse side
effects of chemotherapy [100]. Although the ﬁrst attempts of inhalation
chemotherapy was reported almost 50 years ago [99] and despite clear
advantages of this delivery route for the treatment of primary lung can-
cer andmetastases, inhalation chemotherapy still is not widely used for
treatment. Toxicity of the inhaled drug to normal lung cells and the en-
tire respiratory system after inhalation, penetration of inhaled antican-
cer drug into the bloodstream and associated high systemic toxicity as
well as already mentioned safety concerns for the occupational expo-
sure of healthcare workers that provide inhalation therapy represent
major concerns and potential limitations for the inhalation of chemo-
therapy. While occupational exposure can be prevented by using mod-
ern ﬁlters, the problem of limiting the penetration of inhaled drug into
the systemic circulation and preventing lung toxicity does not have an
effective solution. The development of tumor-targeted delivery system
thatmostly retains in the lungs and does not enter a systemic circulation
is an important task for inhalation chemotherapy of lung cancer. Below
we brieﬂy describe major active components along with delivery vehi-
cles that were already tested for inhalation treatment of lung cancer.
4.7.2. Active components
Many different types of active components have been recently test-
ed for inhalation chemotherapy of lung cancer. They ranged from
Fig. 10. Representative histopathology images of immunosuppressed mice eight days after inoculation of lungs with Aspergillus fumigatus. Mice were treated daily with substances indi-
cated. Control mice received aerosolized sulfobutyl ether-β-cyclodextrin sodium. Lung sections were stained with hematoxylin and eosin and viewed by light microscopy at ×20magni-
ﬁcation.
Modiﬁed from Ref. [96].
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to various types of antibodies and nucleic acids, drug that activates cel-
lular immune response, delivery systems for hyperthermia and radio-
therapy, adjuvant inhalation chemotherapy and combinational therapy.
4.7.2.1. Antibodies. Antibodies represent an attractive alternative to tra-
ditional chemotherapy with anticancer drugs. By their nature, they are
targeted to the speciﬁc site of the action and potentially can provide a
more effective treatment and fewer side effects. Several monoclonal an-
tibodies including cetuximab and bevacizumab targeted to the epider-
mal growth factor receptor and vascular endothelial growth factor
receptor, respectively, have been approved for treatment of lung cancer.
However, systemic delivery of these antibodies represents challenges
because of relatively low accumulation of antibodies in the lungs, high
possibility of their inactivation in the plasma, liver, spleen and other or-
gans. Consequently, attempts have been made to deliver antibodies via
inhalation in order to treat lung cancer.
An innovative Respite™ system that employs surface acousticwaves
(SAW) was developed and tested for inhalation delivery of monoclonal
antibodies against the epidermal growth factor receptor[2]. Itwas found
that a portable SAW nebulizer was able to generate an aerosol and did
not cause antibody fragmentation or their speciﬁc activity. Aerosolized
cetuximab was also tested in nude mouse model of lung cancer sensi-
tive to this drug [101]. The lung cancer was initiated by intratracheal in-
stillation of A431 cancer cellswith EDTA. Itwas found that almost 80% of
inhaled antibodies were retained in the lungs, where the rest of them
were almost equally divided between the mouth and stomach
(Fig. 11). In contrast, free drug was found primarily in the liver and no
free drug was detected in the lungs. It was also found that the inhaled
cetuximab substantially decreased the size of lung tumor.
4.7.2.2. Nucleic acids. Nucleic acids are currently widely used for the
treatment of various diseases, including lung cancer. Viral and non-viral
vectors are being used to suppress oncogenes and/or genes responsible
for the progression of tumor growth or to overcome cancer cells resis-
tance to chemotherapy. The suppression of oncogenes usually is not
very efﬁcient in terms of the suppression of tumor growth. Alternatively,
the suppression of genes responsible for the tumor growth and prolifera-
tion already generated positive results. In addition, the suppression of
genes/proteins responsible for multidrug resistance of cancer cells can
be helpful in enhancing the efﬁcacy of chemotherapy and therefore
should be used together with chemotherapy.
Inhalation gene therapy was studied mainly for the delivery of tumor
suppressor genes, anti-vascular endothelial growth factor (VEGF), epi-
dermal growth factor suppressor (EGF), K-Ras, and immuno-therapy
[100]. The most commonly used approach for the inhalation delivery of
nucleic acids is the formation of complexes with cationic carriers.
Polyethyleneimine (PEI) and its derivatives as linear or branchedpolymers are frequently used for these purposes. The advantages of PEI
include efﬁcient attachments to the airway epithelial cells and introduc-
tion of nucleic acids in the cells and their nuclei, protection of nucleic
acid molecules from degradation and sheer forces during nebulization
[100]. Sometimes PEI-DNA complexes aremodiﬁedwith PEG. Liposomes
and other polymers also are frequently used for DNA complexation to
form stable nanoparticles [22–24,56,57,60,62,73,81,102–105].
Concerning the inhalation delivery of nucleic acids, it should be
stressed that the following delivery systems were used: poly(amino
ester) (PAE) based on glycerol propoxylatetriacrylate (GPT) and
spermine (SPE) copolymer for the delivery of an entire gene in plasmid
or short hairpin RNA (shRNA) [12,13]; complexes of PEI with BC-819—
a novel plasmid DNA which encodes for the A-fragment of Diphtheria
toxin [10] and siRNA targeted to the Wilms' tumor gene [106];
tetrafunctional block copolymers nanospheres containing chemokine
fractalkine [77]; different nanoparticles containing a combination of
various anticancer drugs and suppressors of drug efﬂux transporters
(ABCA, MRP-1, BCL-2) overexpressed in lung cancer cells in order to
simultaneously induce cell death and suppress multidrug resistance
[11,18,20,22–24].
4.7.2.3. Anticancer drugs. Several anticancer drugs have been successfully
delivered into the lungs by inhalation. Most of them include paclitaxel,
cisplatin, doxorubicin, gemcitabine, camptothecin, azacytidine andﬂuo-
rouracil (Fig. 12).
4.7.2.3.1. Paclitaxel. Paclitaxel represents a natural plant-borne anti-
cancer drug ﬁrst isolated from the bark of the Paciﬁc yew, Taxus
brevifolia [107]. The generic name of this drug is “paclitaxel”with trade-
marks deﬁned as Taxol andAbraxane. Paclitaxel targets tubulin interfer-
ing with mitotic spindle function, chromosome segregation, and cell
division [108,109]. Several nontechnology-based carriers were used
for the inhalation delivery of paclitaxel. Liposome-encapsulated formu-
lations of paclitaxel and 9-nitrocamptothecin (9-NC) were proposed
and tested in patients with primary and metastatic lung cancer [4].
Inhalable lung surfactant-based carriers composed of synthetic phos-
pholipids similar to lung surfactants or other phospholipids were also
used for the dry powder delivery of paclitaxel [63,64,110]. The attempts
to use biodegradable microparticles were also undertaken [51,111]. The
results showed a clear perspective of inhalation nanoparticle-based de-
livery of paclitaxel. However, signs of drug toxicity to the upper and
lower respiratory was also registered.
4.7.2.3.2. Cisplatin. Cisplatin, cisplatinum, platamin, neoplatin,
cismaplat or cis-diamminedichloroplatinum(II) (CDDP) is a member of
platinum-containing anti-cancer drugs which also includes carboplatin
and oxaliplatin. These anticancer drugs cause crosslinking of DNA,
which ultimately triggers cell death by apoptosis. Feasibility and effec-
tiveness of inhaled cisplatin analog carboplatinwas evaluated in patients
with non-small cell lung cancer cells [99]. This study revealed a high
Fig. 11. Distribution of cetuximab administered via different routes in mice bearing A431 lung tumors. Representative near infrared images of Xenoﬂuor750™-cetuximab.
Modiﬁed from Ref. [101].
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adverse effects of inhalation delivery of non-targeted anticancer drugs.
4.7.2.3.3. Doxorubicin. Doxorubicin (trade name Adriamycin), also
known as hydroxydaunorubicin and hydroxydaunomycin, is an
anthracycline antitumor antibiotic. Its main action includes intercalat-
ing DNA and inhibition of macromolecular biosynthesis [112]. Doxoru-
bicin is widely used for treatment of different cancers. The liposomal
form of this drug (Doxil) has also been proposed that potentially is
ready and was used for inhalation delivery to the lungs [113,114].
Other carriers were also used of aerosol delivery of doxorubicin [4] in-
cluding dendrimers, n-butylcyanoacrylate, and dextran nanoparticles
[54,115]. In addition, complex delivery systems used for the delivery
of doxorubicin in combination with other active chemotherapeutic
agents were employed for inhalation therapy of lung cancer [19,20,
24]. It was shown that inhalation delivery of doxorubicin enhances
drug exposure to primary lung tumors and metastases and improves
cancer therapy.
4.7.2.3.4. Camptothecin. Camptothecin represents one of cytotoxic
quinoline alkaloids which inhibits topoisomerase I and therefore inter-
feres in the process of DNA replication preventing tumor cell proliferation
[116]. It was ﬁrst isolated from the bark and stem of Camptotheca
acuminate. Several Camptothecin analogs and modiﬁcations were
synthesized including topotecan (hycamtin), irinotecan (CPT-11,
camptosar), DB 67 (AR67), BNP 1350, exatecan, lurtotecan, ST 1481,
and CKD 602. In addition, camptothecin was linked to the cyclodextrin-
based polymer to for a liposomal anti-cancer drug CRLX101 [117].
Liposome-encapsulated formulations of 9-nitrocamptothecin as well as
the carboxylate form of hydroxycamptothecin were also tested [4,118].
4.7.2.3.5. Gemcitabine. Gemcitabine is a nucleoside analog of cytidine
in which the hydrogen atom on the 2′ carbon of deoxycytidine is re-
placed by a ﬂuorine atom. It is marketed as Gemzar by Eli Lilly and Co.
As other analogs of DNA, it replaces a corresponding analog of an
amino acid (in case of gemcitabine–cytidine) and arrests cell divisioncausing apoptosis and therefore arrests tumor growth [119]. Several ap-
proaches were used for inhalation delivery of gemcitabine [4,120].
4.7.2.3.6. Azacytidine. Azacytidine (trade name Vidaza) as well as its
deoxyderivative decitabine represents another nucleoside analog of cy-
tidine with similar to gemcitabine's mechanism of action [121]. It was
found that inhalation delivery of azacytidine substantially improved
pharmacokinetics of the drug and enhanced apoptosis induction in
lung tumors [14].
4.7.2.3.7. Fluorouracil (5-FU). Fluorouracil or 5-FU (trademarked as
Adrucil, Carac, Efudex and Efudix) is a pyrimidine analog that acts pri-
marily as a thymidylate synthase inhibitor to block synthesis of the py-
rimidine thymidine and therefore interferes with DNA replication and
inhibits cancer growth [122]. It was found that inhalation delivery of
5-FU by nebulized aerosols (amixturewith the drug Bisolvon vaporized
by a supersonic nebulizer) enhanced its accumulation in trachea, bron-
chi and regional lymph nodes [123]. In addition, the supercritical
antisolvent process was utilized for the production of 5-ﬂuorouracil
(5-FU) nanoparticles [124].
4.7.2.4. Induction of natural killer cell proliferation. Activation of natural
human immune defense system in order to kill cancer cells represents
a promising alternative to chemotherapy. It was found that aerosol
interleukin-2 induces natural killer cell proliferation in the lung and im-
proved the survival of mice with osteosarcoma lungmetastasis [9]. This
method of induction of natural killer cells demonstrates advantages
over the transfusion of natural killer lymphocytes where infused cells
only temporary reside in the lungs. Two hours after infusion they pre-
dominately accumulated in the liver, spleen, and bone marrow [125].
4.7.2.5. Hyperthermia. An induction of hyperthermia speciﬁcally in
tumor cells denotes another alternative to chemotherapy for the treat-
ment of cancer. A main idea of such therapy includes the delivery to
the tumor vicinity substances (in most cases metal nanoparticles)
Fig. 12. Chemical structures of the most frequently used anticancer drugs for inhalation chemotherapy.
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netic nanoparticles and magnetized thermo-responsive lipid vehicles
were used to: (1) target delivery to the tumor cells by an external
magnetic ﬁeld and (2) treat tumors by increasing temperature of inter-
nalized nanoparticles under the action of high magnitude of this mag-
netic ﬁeld [59,61,84,126]. However, the fear of decomposition of the
treated tumors under the action of hyperthermia, invasion of cancer
cells into the bloodstream and development of metastases limit the en-
thusiasm to this approach.
4.7.2.6. Combination therapy.A combination of severalmethods of killing
cancer cells has advantages over a “simple” cell death induction by one
anticancer agent. Several complex approaches were developed for
treatment of different cancers [26,49]. Some of such approaches were
implemented for inhalation treatment of lung cancer. For instance, a
combination of intravenously injected human natural killer cells and
interleukin-2 delivered as aerosol displayed a synergic effect and sub-
stantially enhanced a survival of micewith osteosarcoma lungmetasta-
ses [9]. A combination of gene therapy expressing ABC10 protein with
aerosol delivery of cisplatinwas also investigated [11]. Another complex
multifunctional approach was developed in our laboratory for treat-
ment of different cancers including their drug resistant variants [43,
44,72,73,105,127]. The approach was based on the simultaneous
targeted delivery of anticancer drug(s) for apoptosis induction and
suppressor(s) of cancer cell resistance to chemotherapy. The applicationof such approach to inhalation treatment of lung cancer showed its high
efﬁcacy accompanied with low adverse side effects upon healthy or-
gans, tissues and cells [19,20,22–25].
4.7.3. Lung tumor imaging and radiosensitization
Nanotechnology approaches have been successfully used to improve
tumor imaging and radiosensitization. When imaging is combined with
cancer therapy, the agent that allows for this combination is usually
called a theranostic (or theragnostic) agent that combines the abilities
to detect/image cancers with therapeutic effects [128]. Most of such
methods are based on the delivery of contrast agents or carriers labeled
with easily detected dyes speciﬁcally to lung tumors, visualization of
this agent by various types of tumor imaging, and, if the delivered
theranostic system contains anticancer drug(s), killing the tumor cells,
and real-time monitoring of the therapeutic outcome. Gadolinium-
based nanoparticles were developed as a theranostic agent for the de-
tection and radiosensitization of lung tumors after their inhalation de-
livery [129]. It was shown that the use of these nanoparticles localized
in tumor nodules of experimental animals and dramatically increased
the survival of animals after radiation treatment. Another approach for
a targeted delivery of a contrast agent directly to lung tumor cells was
developed in our laboratory [126]. The method is based on the use of
PEGylated water soluble Mn3O4 nanoparticles and nanostructured
lipid carriers targeted to the lung tumor cells by the LHRH peptide. In
vivo experiments carried out on mice bearing an orthotopic model of
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the imaging of lung tumors and open possibilities for a simultaneous
targeted treatment of the disease (Fig. 13).
5. Clinical trials and patents of inhaled therapeutics
5.1. Clinical trials
5.1.1. Inhaled granulocyte macrophage colony-stimulating factor (GM-CSF)
GM-CSF is a growth factor capable of stimulating the differentiation
of hematopoietic cells to increase the production of neutrophils, macro-
phages, and dendritic cells. It can also activate established granulocytes
and macrophages [42]. Through its immune activating effects, it is be-
lieved GM-CSF could be used to effectively combat tumor growth. A
number of early phase clinical trials have reported the use of inhaled
GM-CSF in the treatment of lung metastases. The majority of the pa-
tients in the early trials had primary diagnoses of melanoma, renal cell
carcinoma, or osteosarcoma [130–133].
P. Anderson et al. reported one of the ﬁrst dose escalation studies
using recombinant GM-CSF or sargramostim. They used a PARI LC
PLUS nebulizer set (PARI Respiratory Equipment, Inc.) and a standard
air compressor with air ﬂow 3.5–8 L/min. The ﬁrst administration was
performed at the clinic with subsequent doses administered at home
along with at home pulmonary function test (PFT) monitoring. The pa-
tients were dosed at 60 μg twice daily for 7 days at the level 1; 120 μgFig. 13. Enhancement inMRI sensitivity and speciﬁcity by cancer-targetedMn3O4 nanoparticles
in nude mice by the intratracheal instillation of A549 human lung cancer cells transfected with
agent. (C) MRI after injection of biocompatible cancer-targeted Mn3O4 nanoparticles.
Modiﬁed from Ref. [126].twice daily for 7 days at the level 2; 240 μg twice daily for 7 days at
the level three with one week of rest between every dose escalation. A
small number of patients continued the level three dosing with 7 days
of rest between cycles for an additional 2–6 months. Minimal pulmo-
nary toxicities were registered in patients who completed dose escala-
tion. Four of the patients showed stable disease for greater than 6
months with one patient having a complete response [130].
R. Rao et al. reported the results of inhaled sargramostim in 45 pa-
tientswithmetastatic lung disease [133]. The patients had the following
primary diagnoses: melanoma (14 patients), renal cell carcinoma (12
patients), various types of sarcoma (13 patients), and other primary
malignancies (6 patients). The majority of the patients had previously
received treatment for their diseases with twenty one patients having
received four or more therapies. The average duration of treatment
was 4.6 months. A disease progression was the most common reason
for discontinuation of therapy. Of all the patients evaluated, three
showed partial regression of lung tumors while twenty one patients
showed stable disease. The patients who responded showed beneﬁts
of therapy for an average of 10 months. Overall, the patients tolerated
the treatment very well with twenty eight patients (62%) reporting no
toxicities. Fourteen patients (31%) in the study complained of mild pul-
monary symptoms such as dyspnea, cough, and wheezing, however,
some of these effects could be contributed to the presence of lung me-
tastases. To study the mechanism of action of GM-CSF, one patient
who had previously received no therapy and was diagnosed with. (A) Representative light or bioluminescence IVIS optical imaging. Lung tumorwas created
luciferase. (B–C) Representative magnetic resonance imaging. (B) MRI without a contrast
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cytotoxic T lymphocytes in peripheral blood. After two months of
treatment, this patient showed an increase in melanoma speciﬁc cyto-
toxic T-lymphocytes (CTL) [133]. Encouraged by the safety data and
the increase in cytotoxic T-lymphocytes in the patient that was evaluat-
ed, investigators began a second dose escalation study to determine the
optimal dosing regimen required to induce a robust immunologic re-
sponse in a majority of patients with acceptable side effects.
Markovic et al. report the results of forty patients with metastatic
melanoma treated with escalating doses of GM-CSF ranging from 500
to 2000 μg twice daily with doses increasing at 250 μg intervals [132].
The patients were treated in 28 day cycles with dosing on days 1–7
and days 15–21. Patients' blood samples were evaluated for cytotoxic
T-lymphocytes (CTL) before treatment, after two cycles of treatment,
and every other cycle thereafter if therapy was continued. If a patient
had detectable anti-melanoma CTL before treatment, a ﬁvefold increase
in CTL after the ﬁrst two cycles of treatment was considered a positive
immune response. If the CTL were not detectable, conﬁrmation of CTL
was considered a positive immune response. At a given dose level if 3/
5 patients showed an immune response, another 5 patients would be
enrolled at that dose. If 7/10 patients had an immune response, that
would be deﬁned as an immunologically effective dose. Among those
treatedwith the 1250 μg doseor lower, two patients exhibited a positive
immune response where they developed detectable anti-melanoma
CTL. In those treated with doses 1500 μg or higher, three patients had
a positive immune response by showing detectable CTL to speciﬁc mel-
anoma antigens. In the two highest dose groups, 6/11 patients devel-
oped a 2–4 fold increase in previously detectable CTL. These results
did not establish an immunogenic effective dose, but the investigators
also did not reach a maximum tolerated dose. Of the patients treated,
two patients (1750 μg, 2000 μg dose) experienced grade 3 or higher tox-
icities requiring discontinuation of therapy. One patient in the 1000 μg
dose level experienced grade 3 fatigue and grade 2 dyspnea but could
not continue at a lower dose due to disease progression. A number of
lower grade toxicities such as cough, anemia, fatigue, dizziness, and
nausea were also reported. Pulmonary function tests were monitored
for all patients and there were no signiﬁcant changes requiring discon-
tinuation of therapy [132]. These results imply that the use of inhaled
GM-CSF may have some utility in developing anti-melanoma CTL in pa-
tients, however, further evaluation of the appropriate dose and the
treatment schedule is required.
5.1.2. Inhaled recombinant human interleukin-2 (rhIL-2)
rhIL-2 is a chemokine approved for the treatment ofmetastatic renal
cell carcinoma and metastatic melanoma. It is believed that this inter-
leukin can enhance lymphocyte cytotoxicity, increase the effects of lym-
phocyte activated and natural killer cells, and increase interferon
gamma production [33]. Inhaled rhIL-2 used for the treatment of renal
cell carcinoma patients with lung metastases has been studied by a
number of investigators [134–137]. Huland et al. report the comparison
of inhaled IL-2 combined with low dose sub-cutaneous (SC) IL-2 versus
historical controls receiving standard dose IL-2 therapy. The inhalation
arm treatment consisted of 3.3 MIU rhIL-2 SC once daily with 6.5 MIU
rhIL-2 administered via nebulizer. Standard therapy included cycles of
intravenous therapy at 18 MIU/m2/day or cycles of SC therapy adminis-
tered at 3.6–18 MIU per day. The results showed an overall response
rate of 45% in the inhalation arm vs 33% in the systemic treatment
arm. The inhalation arm also showed better survival rates at the 1, 3,
and 5 year marks. The side effects proﬁle for the inhalation group ap-
peared more favorable compared to systemic therapy. The most com-
mon side effect noted in the inhaled rhIL-2 was cough which was
most commonly reported after the last inhalation of the day. Patients
in both groups also reported constipation, diarrhea, nausea, and fatigue
[135]. Overall, inhalation treatment was shown to provide better stabi-
lization of disease with a more tolerable side effect proﬁle as compared
to systemic IL-2.Merimsky et al. reported their clinical experience with a similar dos-
ing regimen of 0.9–1.8MIU SC daily combinedwith 6MIU inhaled three
times a day (18 MIU daily). The SC injections were discontinued after
the ﬁrst 10 patients refused systemic therapy due to side effects. One
of forty patients (2.5%) had a partial responsewhile twenty twopatients
(55%) showed stable disease with the median time until progression of
8.7 months. The side effect proﬁle was similar to that previously de-
scribedwith cough andweakness reported as themost common side ef-
fects with dyspnea, fever, sleepiness, asthenia, decreased appetite, and
abdominal pain reported by less than three patients each [136]. Al-
though the investigators did not see a large number of patients with a
reduction in tumor size, stabilization in a large portion of patients
with limited side effects could be seen as a success when compared to
the natural course of disease.
The studies of inhaled rhIL-2 in metastatic renal cell carcinoma have
shown the feasibility of the treatmentwith limited toxicity as compared
to high dose systemic therapy. A limited beneﬁt with inhalation therapy
was seen although the few trials have shown varying levels of response
in the patients studied. The administration of the treatment is conve-
nient as the therapy can be administered at home by the patient as com-
pared with traditional chemotherapy. However, the administration of
the aerosols three to ﬁve times per day may be problematic for some
patients.
Recently, Posch et al. reported the results of rhIL-2 inhalation in
combinationwith dacarbazine treatment in stage IVmalignantmelano-
ma patients as well as the use of prophylactic rhIL-2 dosing to prevent
recurrence post resection of lung metastases. The study enrolled 15 pa-
tients into the treatment arm and 5 into the prophylaxis arm. Although
the number of patients was too small for statistical analysis, four (27%)
patients showed a partial response and ﬁve (33%) had stabilization of
disease. In the prophylaxis group, 4 patients received treatment for a
median of 24.5monthswith no recurrence of lungmetastases, however,
the patients eventually experienced disease recurrence at other sites re-
quiring systemic therapy [137]. Overall, the inhaled rhIL-2 trials have
shown to be effective in prolonging survival in metastatic lung disease.
There is still a need to determine the optimal dosing schedule as the tri-
als have used varying dosing regiments with or without systemic ther-
apy. It is also unclear whether it is best used in combination with
systemic therapy, as single agent therapy, or as prophylaxis post-
surgical resection of lung tumors. These questions, along with efﬁcacy
data in more patients, need to be answered before inhaled IL-2 enters
a mainstay of lung carcinoma treatment.
5.1.3. Inhaled chemotherapy solutions
Inhalation chemotherapy was ﬁrst described in the late 1960s and
has since been explored as a means to target lung malignancy in the
hope of reducing systemic side effects [100]. In the past ten years,
there have been a number of clinical trials that have evaluated the
effectiveness of nebulized doxorubicin, gemcitabine, and carboplatin
[99,138–140].
G. Otterson et al. reported the results of a dose escalation study using
doxorubicin nebulized via an OncoMyst devicewhich consisted of a Pari
LC Plus nebulizer (PARI Respiratory Equipment, Inc.) containedwithin a
system to capture stray aerosols. The droplet size produced by this sys-
tem was reported to be 2–3 μm in size allowing for effective deep lung
delivery [140]. The patients were dosed with doxorubicin solution via
inhalation once every three weeks at doses ranging from 0.4 mg/m2 to
9.4 mg/m2. A total of 53 patients were enrolled in the study at varying
dosing levels. Limited pharmacokinetic analysis showed some drug
was absorbed through the lungs, although the Cmax was well below
the levels achieved after IV administration. The investigators report at
a dose of 9.4 mg/m2 two of four patients developed grade 3 or higher
toxicities. At the 7.5mg/m2 dose, only one patient of eleven experienced
a dose limiting toxicity leading the investigators to designate this as the
maximum safe dose of inhaled doxorubicin solution. Grade 1/2 cough
was reported in 27/53 patients. Other tolerable side effects such as
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and otherswere reported [140]. Based on these results, the investigators
further studied the use of inhaled doxorubicin in combination with
standard doses of cisplatin and docetaxel. Doses of 6 mg/m2 and
7.5 mg/m2 were evaluated with the primary objectives of the study
was to determine the appropriate dose to use in combination with
systemic therapy as well as achieving an overall response rate
(complete + partial response) greater than 35%. At completion of the
trial, 24 patients were evaluated with seven patients showing positive
response to treatment. This number did not meet the predeﬁned re-
sponse rate, and the investigators recommended against progressing
to a phase III study of this regimen [139].
E. Lemarie et al. demonstrated a feasibility of inhaled gemcitabine
in eleven patients. Dose escalation showed a maximum tolerated
dose of 3 mg/kg gemcitabine used in the nebulizer [138]. Scinti-
graphic analysis using
99
mTc-diethylene triamino pentaacetic acid
mixed with gemcitabine during the ﬁrst inhalation of treatment
showed on average 43% of the inhaled gemcitabine reached the
lung tissues while on average 47% was detected in the upper airways
and stomach. Toxicities reported included one patient (3 mg/kg
dose) with grade 4 bronchospasm, and 8 patients were noted to
have cough during and after nebulization. Other side effects reported
included fatigue, nausea, anorexia, and others. Pharmacokinetic
analysis showed limited absorption of drug which correlated with
the total drug exposure to the lung, however, there were no severe
systemic side effects reported [138]. This small trial conﬁrmed the
ability of nebulized chemotherapy to reach the lungwith limited sys-
temic side effects.
P. Zarogoulidis et al. reported the use of inhaled carboplatin in com-
bination with 100mg/m2 IV docetaxel [99]. Groups A, B and C consisted
of IV carboplatin, 1/3 dose inhalation carboplatin and 2/3 dose IV, and
full dose inhaled carboplatin, respectfully, combined with docetaxel.
Toxicity data for each group showed awide range of adverse side effects
in all three groups. Neutropenia occurred less frequently with the inha-
lation treatments as compared to the control group with only 1/20 pa-
tients in group C experiencing grade 3 neutropenia. When looking at
pulmonary side effects, their incidence increased with increasing in-
haled carboplatin, however, some such as cough, resolved a few days
after completion of the inhalations. Gastrointestinal side effects also
seemed to increase in occurrence in the inhalation treatment groups.
Median survival beneﬁt was seen in groups B and C with survival bene-
ﬁts of 64 and 25 days, respectfully, as compared to the control group
[99]. These results show promise that inhaled chemotherapy can be
useful in helping patients with lung malignancies. However, an exten-
sive investigation needs to be done in order to choose the correct dose
and formulation of inhaled therapy as well as manage toxicity proﬁles
distinct to the inhalation treatments.
5.1.4. Inhaled drug-loaded nanoparticles
There have been relatively few clinical trials evaluating the use of
inhaled nanoparticle systems for the treatment of lungmalignancies.
The few trials that have been reported have focused on the use of ei-
ther liposomal cisplatin or 9-nitro-20-camphothecin [141–143]. C.
Verschraegen et al. reported a dose escalation trial of inhaled liposo-
mal 9-nitro-20-camphothecin (9NC) in 24 patients. Liposomes were
composed of dilauroylphosphatidylcholine (DLPC) and contained 2%
9NC. Initial dosing began at 6.7 μg/kg/day of 9NC and reached maxi-
mum of 26.6 μg/kg/day 9NC. 13.3 μg/kg/day 9NC was considered a
safe dosing level for future studies as all patients tolerated the treat-
ment well. The majority of side effects across all dosing levels were
grade 1 or 2 with cough, nausea, and fatigue occurring most fre-
quently. Although efﬁcacy was seen as partial remission in two pa-
tients, this study only established that liposomal 9NC could be
safely administered to patients with lung carcinoma [142].
B. Wittgen et al. evaluated liposomal cisplatin in a dose escalation
study in patients with pulmonary carcinoma [143]. Liposomescomposed of dipalmitoylphosphatidylcholine (DPPC) and cholesterol
were loaded with cisplatin. The doses ranged from 1.5 mg/m2 to
60mg/m2with a total of 17 patients evaluated. Themost commonly re-
ported side effects included fatigue, nausea, vomiting, and pulmonary
changes although most of these were either grade 1 or 2 [143]. In this
study, 12 patients experienced stable disease. Based on the relative safe-
ty of this cisplatin formulation, A. Chou et al. reported its use in the in-
halation treatment of osteosarcoma metastatic to the lungs [141]. A
total of 19 patients were treated with 24 mg/m2 or 36 mg/m2 doses of
liposomal cisplatin. As seen in previous trials, pulmonary side effects
weremost commonly reported followed by gastrointestinal side effects.
The results of this trial showed that three patients had a complete re-
sponse after surgical resection post inhalation treatment while one pa-
tient had a partial response to treatment [141]. These results show that
inhaled liposomal cisplatin is safe and tolerable to patients and can pro-
vide a beneﬁt to patients with metastatic lung disease.5.1.5. Inhalation cystic ﬁbrosis (CF) therapy
Cystic ﬁbrosis is a disease cause by defects in the cystic ﬁbrosis
transmembrane conductance regulator (CFTR) which can affect mul-
tiple organ systems leading to the buildup of thick mucus, inﬂamma-
tion, and injury in the lung. Some small molecule drugs that improve
the symptoms in certain CF mutations were developed, however,
they are only effective for a small percentage of patients [144]. This
opens the need for the development of a treatment approach that
can be used in all patients. Gene therapy was researched extensively
for these purposes. Both viral and non-viral delivery systems were
investigated. Two clinical trials of adeno-associated virus (AAV) car-
rying cystic ﬁbrosis transmembrane conductance regulator (CFTR)
cDNA have shown safety but limited efﬁcacy data [145,146]. Early
trials using cationic liposomes and DNA plasmids delivered to nasal
epithelium showed mixed results [147–149]. One trial reported
that nasal delivery was safe, however, did not lead to positive trans-
fection of collected samples [149]. Hyde et al. reported no inﬂamma-
tory response to the liposome/DNA complex as well as on average 6/
8 patients after each dose positive for transfection with the plasmid
[148]. Alton et al. achieved successful transfection using cationic li-
posome system for plasmid delivery to the lung and nasal epitheli-
um. Upon lung delivery of the formulation, 7/8 patients developed
mild ﬂu like symptoms which resolved within two days of therapy.
Ruiz et al. also reported an inﬂammatory response to inhalation
treatment with cationic lipid DNA complexes [150]. The early trials
have established feasibility of transfection as well as safety concern
for future trials. Recently, a large randomized placebo controlled
phase IIb trial was undertaken to determine the efﬁcacy of inhalation
cationic liposome plasmid DNA formulation. The subjects were treat-
ed with once monthly doses of 13.5 mg of plasmid DNA complexed
with 75 mg liposomes for one year. The primary end point is the
change in predicted FEV1 [151]. This trial hopefully help to deter-
mine the clinical beneﬁts of non-viral mediated CFTR gene therapy
delivered via inhalation.5.2. Patents
Recently, there have been a number of patent applications for
nanoparticle delivery systems. The systems claim a variety of diverse
applications and advantages over traditional drug delivery methods.
Table 1, shows some typical examples of patents or patent applica-
tions for the inhalation treatment of diseases. The patents/applica-
tions were identiﬁed using a Google patent search for “drug loaded
nanoparticles for lung delivery” and limited to those submitted in
2013, 2014, or 2015. The search also focused on technologies de-
signed speciﬁcally for lung therapy excluding those patents that
made very broad claims for the application of their inventions.
Table 1
Recent patent and patent applications for nanoparticle platforms for inhalation delivery of therapeutics.
Patent/application
number
Nanoparticle platform Particle size or molecular
weight
Therapeutic agent(s) Possible applications
US20140186290 Polystyrene 500 nm Empty particles Dispersal of thick mucus produced by
various lung diseases and diseases at
other mucosal surfaces [152]
US20150126589 Polyethyleneimine (PEI) 1–1000 kDa mRNA for various target genes Treatment of diseases due to defective or
insufﬁcient production of proteins and
other diseases targeted by gene therapy
[153]
US20150038556 Polyethylimine (PEI), protamine,
poly-L-lysine (PLL), cationic lipids
Varies with delivery platform CFTR mRNA Correction of CFTR gene function in cystic
ﬁbrosis patients [154]
US8440231 Variable biodegradable polymer types
that swell in size upon delivery to the
lungs
Mass median aerodynamic
diameter less than 5 μm
Any number of therapeutics
directed to treat disease
Treatment of any number of pulmonary
diseases [155]
US20130273164 Liposomes or nanostructured lipid
carriers
1–1000 nm Lipid soluble small molecule drugs,
peptides, or siRNA's
Inhalation treatment of a number of
inﬂammatory pulmonary diseases [156]
WO2014145606 Silica particles 1–25 nm Fluorescent molecules, radionuclides,
targeting peptides, oligonucleotides,
and any number of small molecule
drugs
Formulation may be delivered by any
number of routes for the treatment and
imaging of various diseases [157]
WO2014144285 Poly(ethylene glycol)–poly(propylene
oxide)–poly(ethylene glycol) triblock
co-polymer
50 nm–1000 nm composed of
varying molecular weight
polymers
Meropenem derivatives Inhalation treatment of pulmonary
infection including those caused by
Pseudomonas aeruginosa [158]
US20140302147 Distearoylphosphatidylcholine (DSPC)
plus calcium chloride
1–5 μm Glycopyrrolate, indacatrol,
mometasone
Possible treatment of diseases such as
COPD, asthma, idiopathic pulmonary
ﬁbrosis, and others [159]
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Analysis ofmodern achievements of various lung diseases by inhala-
tion of nanomedicines clearly shows advantages of direct local delivery
of nanopharmaceutics speciﬁcally to the diseased cells in the lungs.
Based on the analysis of the literature data and our own extensive expe-
rience in this ﬁeld, we can conclude that the future of nanotechnology-
based inhalation treatment of lung diseases belongs to the targeted
multifunctional approach where therapeutic agents are delivered spe-
ciﬁcally to the diseased cells in the lungs together with suppressors of
their resistance to the therapy. In addition, most probably such ad-
vanced multifunctional treatment will include the delivery of several
drugs with different mechanisms of action, enhance the efﬁcacy of
treatment of lung diseases and limit adverse side effects on healthy
tissues.
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